Enriched Trials Not Just About Marker-Positive Patients, FDA Says

Without clear-cut evidence that a drug will not work in patients without a predictive marker, enrichment strategies should allow for collecting some data in the marker-negative population, FDA says in draft guidance.

Information about a drug’s effect in patients without a characteristic that predicts efficacy can be just as important as the data for those with the predictive marker when trying to prove that marker’s value.

FDA makes this case in its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America